Colorectal Cancer

Howard M. Ross, MD, discusses the role of the microbiome colorectal cancer.

Peter Kozuch, MD, discusses the role of circulating tumor DNA in colorectal cancer.

The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.

Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.

The addition of fruquintinib to best supportive care improved overall survival compared with BSC alone in patients with metastatic colorectal cancer who progressed on standard chemotherapy and relevant biologic agents, and who had progressed on or were intolerant to trifluridine/tipiracil and/or regorafenib.

Experts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

The FDA has lifted a clinical hold on the phase 1b KEYNOTE-B79 trial, which is evaluating the safety and clinical activity of CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer.

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.

Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.

A look at how the molecular testing landscape in colorectal cancer is evolving.

Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.

Howard M. Ross, MD, discusses the increase in colon and rectal cancer in young patients.

John L. Hays, MD, PhD, discusses expanding treatment options for HER2-positive colorectal cancer.

A 3-month course of oxaliplatin produced disease-free survival noninferior to a 6-month course in patients with high-risk stage II and III colorectal cancer.

Nivolumab alone or in combination with ipilimumab continued to demonstrate sustained clinical benefit as second- and first-line therapy, respectively, in patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

The combination of nivolumab and ipilimumab generated a 100% response rate in patients with mismatch repair–deficient colon cancer and a 29% response rate in patients with MMR-proficient disease.

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

The addition of nivolumab to FOLFOXIRI and bevacizumab resulted in encouraging responses when used as frontline treatment in patients with advanced or metastatic colorectal cancer harboring RAS or BRAF mutations, irrespective of microsatellite status.

Experts describe which patients should be screened for HER2 amplification in colorectal cancer and how best to detect it.

A pathologist explains how she chooses between a variety of molecular testing technology options in colorectal cancer.

Patients with previously treated metastatic HER2-positive colorectal cancer experienced clinically meaningful and durable responses to treatment with tucatinib plus trastuzumab, according to data from the phase 2 MOUNTAINEER trial.

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey’s only National Cancer Institute-Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable tumors.